5965-66-2

Basic information

• Product Name: BETA-D-LACTOSE
• Synonyms: 4-o-beta-d-galactopyranosyl-beta-d-glucopyranos;4-O-Hexopyranosylhexopyranose;Lactose, beta-;4-O-BETA-D-GALACTOPYRANOSYL-BETA-D-GLUCOPYRANOSE;B-4-(B-D-GALACTOSIDO)-D-GLUCOSE;BETA-D-GAL-[1->4]-BETA-D-GLC;BETA-D-LACTOSE;BETA-LACTOSE
• CAS NO: 5965-66-2
• Molecular Formula: C12H22O11
• Molecular Weight: 342.3
• EINECS: 227-751-9
• Product Categories: Oligosaccharide Compounds;Oligosaccharides
• Mol File: 5965-66-2.mol
• Article Data: 11

Chemical Properties

• Melting Point: 224 °C
• Boiling Point: 397.76°C (rough estimate)
• Flash Point: 357.752 ºC
• Appearance: /
• Density: 1.5900
• Refractive Index: 1.5376 (estimate)
• Storage Temp.: Room Temp
• PKA: 12.02±0.70(Predicted)
• Water Solubility: Soluble in water.
• Merck: 14,5343
• CAS DataBase Reference: BETA-D-LACTOSE(CAS DataBase Reference)
• NIST Chemistry Reference: BETA-D-LACTOSE(5965-66-2)
• EPA Substance Registry System: BETA-D-LACTOSE(5965-66-2)

Safety Data

• Safety Statements: 24/25
• WGK Germany: 3
• RTECS: LZ5776360
• TSCA: Yes
• Hazardous Substances Data: 5965-66-2(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

β-D-Lactose is used in the pharmaceutical industry to make tablets. It acts as a nutrient and as a filler used in pills. It is utilized in the dilution of heroin. Further, it is used to sweeten stout beer.

Definition

ChEBI: The beta-anomer of lactose.

Biochem/physiol Actions

Beta-Lactose is the beta-pyranose form of the compound lactose.

Downstream Products

• 644-76-8 1,6-anhydro-β-D-galactopyranose 
• 498-07-7 levoglucosan 
• 83073-75-0 PA-lactitol 
• 53144-51-7 (2'RS)-2',3'-epoxyprop-1'-yl-β-D-galactopyranoside 
• 50-99-7 D-glucose 
• 88970-25-6 4-O-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-2,3,6-tri-O-benzyl-1,5-D-gluconolactone 
• 87-81-0 D-tagatose 
• 59-23-4 D-Galactose 
• 4618-18-2 lactulose 
• 85054-31-5 GlcNAc-β1,6-GalNAc-α1-OBn 
• 87866-15-7 Gal-β1,3[GlcNAc-β1,6]-GalNAc-α1-OBn 
• 74-90-8 hydrogen cyanide 
• 499-16-1 lactitol 
• 2280-44-6 D-Glucose 

Relevant articles and documents

PHARMACEUTICAL ANTIRETROVIRAL COMPOSITION

The present invention relates to a pharmaceutical antiretroviral composition comprising (i) a nucleoside reverse-transcriptase inhibitor selected from lamivudine and emtricitabine, (ii) extended release nevirapine, and (iii) tenofovir; a process for preparing such composition and the use of such composition in medicine, particularly for the prophylaxis and/or treatment of diseases caused by retroviruses.

Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract

Disclosed herein is a pharmaceutical composition having preventative and therapeutic effects on liver diseases, comprising an extract from Lonicera caerulea L. var. edulis. The composition has preventative and therapeutic effects on hepatitis, liver cirrhosis, fatty liver, and the like.

Synthesis and characterization of bis(glycosylamino)benzenes based on reducing disaccharides

Synthesis of bis(glycosylamino)benzenes, derived from disaccharides lactose, maltose, and cellobiose, by direct condensation and their characterization are described.